Repositioning Candidate Details
| Candidate ID: | R0697 |
| Source ID: | DB05088 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Tetrathiomolybdate |
| Synonyms: | Thiomolybdate; Tiomolibdate ion |
| Molecular Formula: | MoS4 |
| SMILES: | [S-][Mo]([S-])(=S)=S |
| Structure: |
|
| DrugBank Description: | Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body. |
| CAS Number: | 16330-92-0 |
| Molecular Weight: | 224.19 |
| DrugBank Indication: | Investigated for use/treatment in liver disease and pulmonary fibrosis. |
| DrugBank Pharmacology: | Tetrathiomolybdate demonstrated the ability to reduce toxic free copper levels and substantially improve clinical neurologic outcomes in Wilson’s patients. Studies also showed it is capable of specifically inhibiting chronic fibrotic disease processes in the lung. |
| DrugBank MoA: | Tetrathiomolybdate has demonstrated the ability to inhibit fibrosis in a number of well established animal models through the sequestration of available copper and inhibition of key fibrotric cytokines, including secreted protein acid rich in cysteine (SPARC), NFkappaB, TGF-beta, FGF-2, IL-1, IL-6, IL-8, and connective tissue growth factor (CTGF). |
| Targets: | Amyloid beta A4 protein |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|